Drug Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Therapy
Research reports from Memorial Sloan Kettering Cancer Center provide new insights into cancer therapy
March 2nd, 2007
Current study results from the report, "Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug," have been published. According to recent research published in the journal Nature Biotechnology, "In our quest to understand why dimethyl sulfoxide (DMSO) can cause growth arrest and terminal differentiation of transformed cells, we followed a path that led us to discover suberoylanilide hydroxamic acid (SAHA; vorinostat (Zolinza)), which is a histone deacetylase inhibitor. SAHA reacts with and blocks the catalytic site of these enzymes." "Extensive structure-activity studies were done along the path from DMSO to...
Source: Drug Week (2007-03-02)
|
